艾索基因

最新新闻

• 评级变动
  A Quick Look at Today's Ratings for AxoGen(AXGN.US), With a Forecast Between $48 to $55
  \u5e02\u573a\u8d44\u8baf · 2026/4/30
• 评级变动
  Jefferies Maintains AxoGen(AXGN.US) With Buy Rating, Raises Target Price to $50
  \u5e02\u573a\u8d44\u8baf · 2026/7/6
• 评级变动
  CCORF Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/5/4
• 评级变动
  Raymond James Maintains AxoGen(AXGN.US) With Buy Rating, Raises Target Price to $53
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• 评级变动
  A Quick Look at Today's Ratings for AxoGen(AXGN.US), With a Forecast Between $50 to $50
  \u5e02\u573a\u8d44\u8baf · 2026/4/29
• 评级变动
  CCORF Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/4/17
• 评级变动
  Truist Financial Initiates AxoGen(AXGN.US) With Buy Rating, Announces Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/8/26
• 评级变动
  H.C. Wainwright Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $39
  \u5e02\u573a\u8d44\u8baf · 2026/2/27
• Truist Financial Maintains AxoGen(AXGN.US) With Buy Rating, Announces Target Price $53
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  CCORF Maintains AxoGen(AXGN.US) With Buy Rating, Raises Target Price to $45
  \u5e02\u573a\u8d44\u8baf · 2026/4/24
• 评级变动
  A Quick Look at Today's Ratings for AxoGen(AXGN.US), With a Forecast Between $53 to $55
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• CCORF Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  Lake Street Maintains AxoGen(AXGN.US) With Buy Rating, Raises Target Price to $50
  \u5e02\u573a\u8d44\u8baf · 2026/4/23
• Truist Financial Maintains AxoGen(AXGN.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• Wells Fargo Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $48
  \u5e02\u573a\u8d44\u8baf · 2026/10/3
• 评级变动
  Lake Street Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/4/27
• 评级变动
  Jefferies Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  Mizuho Securities Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/4/13
• Lake Street Maintains AxoGen(AXGN.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/10/5
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), AxoGen (AXGN) and Biohaven Ltd. (BHVN)
  TipRanks · 2026/9/30

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。